secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2026-09-29T12:00:30+00:00
Accession:  0001213900-26-104317
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Allarity expands in-house lab to proteomics and cell line research, citing no cash-runway impact
--------------------------------------------------------------------------------

- In-house medical laboratory adds proteomics and cell line research, building on existing transcriptomics work and CLIA clinical testing services.
- nCounter Pro instrument now also runs the nCounter Human Tumor Signaling Protein Panel, which measures approximately 300 protein targets.
- Company says the expansion will not affect its current cash runway and may generate cost efficiencies by enabling more research in-house.
- CEO Thomas Jensen: broader molecular insights support stenoparib (2X-121), a dual PARP and WNT pathway inhibitor in Phase 2 development.
- New capabilities broaden the research services Allarity can offer to existing and prospective external partners.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390026104317/0001213900-26-104317-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390026104317/ea0306873-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-104317

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer